The BSRBR-RA study tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) and other targeted therapies in the UK to monitor the long-term safety of these drugs.
To find out more about the study, please visit our main site.
Latest blog posts
JAK Inhibitors in the BSRBR-RA
Read about some of the recent research from BSRBR-RA looking at JAK inhibitors. Bit of background about you Hello, my name is Zixing Tian, I am an epidemiologist with a research focus on rheumatoid arthritis (RA). I work on the BSRBR-RA study, where I recently...
Working With Patient Support Organisations – Why Is This Important?
The BSRBR-RA study is fortunate to have strong links with a national patient organisation, National Rheumatoid Arthritis Society (NRAS), and have held numerous focus groups, surveys and meetings with them to ensure that the patient voice is always considered within...
New results from the study: Research on bDMARDs and Rheumatoid Arthritis
We are happy to share our latest research findings: 'Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?' This analysis, performed by Dr Kim Lauper,...
Read about some of the recent research from that BSRBR-RA looking at biosimilars.
Lianne, you did the research, tell us about yourself…Hello, my name is Lianne, I am an epidemiologist at the University of Manchester. For the past 12 years I have been a researcher working on the BSRBR-RA study. In addition, I also have a research interest in the...
The Associate Principal Investigator Scheme Experience
The BSRBR-RA Study (UK CRN ID: 7302) is part of the NIHR Associate Principal Investigator Scheme. We asked George Nowell, a rheumatology speciality trainee at Stockport NHS Foundation Trust, about his experience as an associate principal investigator on the BSRBR-RA,...
Join Us at the BSR Rheumatology Conference 24-26 April 2024!
We are thrilled to extend a warm invitation to join our sessions at the BSR’s Rheumatology conference. Held between 24th – 26th April 2024 at the ACC in Liverpool, this conference promises a wide variety of talks across all aspects of rheumatology and rheumatology...
Tyenne (tocilizumab) – the new biosimilar on the block
What is Tyenne? Tyenne is the first tocilizumab (interleukin-6) biosimilar that has recently been approved by the European Medicines Agency (EMA) for the treatment of moderate to severe rheumatoid arthritis in adults. It is now starting to be prescribed in the UK and...
Welcome to our new blog for the BSRBR-RA study!
What is the BSRBR-RA?BSRBR-RA is the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. The primary aim of the study is to monitor the long term safety of biologics, biosimilars and other targeted therapies. Originally set up in 2001, the...
NIHR Associate Principal Investigator Scheme
The BSRBR-RA Study (UK CRN ID: 7302) has joined the NIHR Associate Principal Investigator Scheme. The Associate Principal Investigator (PI) Scheme is a six month in-work training opportunity, providing practical experience for healthcare professionals starting their...
Switching from the original etanercept (the originator) to an etanercept biosimilar for rheumatoid arthritis (RA) – patients do just as well as those who remained on the originator.
Researchers: Lianne Kearsley-Fleet, Aasiyah Rokad, Man-Fung Tsoi, Sizheng Steven Zhao, Mark Lunt, Kath D. Watson, BSRBR-RA Contributors Group, Kimme L. Hyrich. What was already known? Etanercept is one of the main treatment options for patients with rheumatoid...
Contact Us
+44 (0) 161 306 6000
Recent Comments